Peripheral Neuropathic Pain - Pipeline Review, H1 2016

  • ID: 3734766
  • Drug Pipelines
  • 70 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AnaBios Corporation
  • Chromocell Corporation
  • Eli Lilly and Company
  • GW Pharmaceuticals Plc
  • Nektar Therapeutics
  • Phosphagenics Limited
  • MORE
Peripheral Neuropathic Pain - Pipeline Review, H1 2016

Summary

‘Peripheral Neuropathic Pain - Pipeline Review, H1 2016’, provides an overview of the Peripheral Neuropathic Pain pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Peripheral Neuropathic Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Peripheral Neuropathic Pain and features dormant and discontinued projects.

Our report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Peripheral Neuropathic Pain
- The report reviews pipeline therapeutics for Peripheral Neuropathic Pain by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Peripheral Neuropathic Pain therapeutics and enlists all their major and minor projects
- The report assesses Peripheral Neuropathic Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Peripheral Neuropathic Pain

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Peripheral Neuropathic Pain
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Peripheral Neuropathic Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AnaBios Corporation
  • Chromocell Corporation
  • Eli Lilly and Company
  • GW Pharmaceuticals Plc
  • Nektar Therapeutics
  • Phosphagenics Limited
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Peripheral Neuropathic Pain Overview

Therapeutics Development

Pipeline Products for Peripheral Neuropathic Pain - Overview

Pipeline Products for Peripheral Neuropathic Pain - Comparative Analysis

Peripheral Neuropathic Pain - Therapeutics under Development by Companies

Peripheral Neuropathic Pain - Therapeutics under Investigation by Universities/Institutes

Peripheral Neuropathic Pain - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Peripheral Neuropathic Pain - Products under Development by Companies

Peripheral Neuropathic Pain - Products under Investigation by Universities/Institutes

Peripheral Neuropathic Pain - Companies Involved in Therapeutics Development

Achelios Therapeutics, Inc.

AnaBios Corporation

Chromocell Corporation

Eli Lilly and Company

GW Pharmaceuticals Plc

Nektar Therapeutics

Phosphagenics Limited

Spherium Biomed S.L.

Sunovion Pharmaceuticals Inc.

Zynerba Pharmaceuticals, Inc.

Peripheral Neuropathic Pain - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

AXPN-03 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

CC-8464 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

DSP-2230 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

duloxetine hydrochloride DR - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ECL-1 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ketoprofen - Drug Profile

Product Description

Mechanism of Action

R&D Progress

nabiximols - Drug Profile

Product Description

Mechanism of Action

R&D Progress

NKTR-171 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

oxycodone ER - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecule 1 for Peripheral Neuropathic Pain - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecule 2 for Peripheral Neuropathic Pain - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Small Molecule for Pain - Drug Profile

Product Description

Mechanism of Action

R&D Progress

SP-15001 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

ZYN-001 - Drug Profile

Product Description

Mechanism of Action

R&D Progress

Peripheral Neuropathic Pain - Recent Pipeline Updates

Peripheral Neuropathic Pain - Dormant Projects

Peripheral Neuropathic Pain - Discontinued Products

Peripheral Neuropathic Pain - Product Development Milestones

Featured News & Press Releases

Jul 28, 2014: Phosphagenics Provides Update on TPM/Oxycodone patch

Jul 06, 2012: Lilly Obtains Six Months US Pediatric Exclusivity For Cymbalta

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Peripheral Neuropathic Pain, H1 2016

Number of Products under Development for Peripheral Neuropathic Pain - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Investigation by Universities/Institutes, H1 2016

Peripheral Neuropathic Pain - Pipeline by Achelios Therapeutics, Inc., H1 2016

Peripheral Neuropathic Pain - Pipeline by AnaBios Corporation, H1 2016

Peripheral Neuropathic Pain - Pipeline by Chromocell Corporation, H1 2016

Peripheral Neuropathic Pain - Pipeline by Eli Lilly and Company, H1 2016

Peripheral Neuropathic Pain - Pipeline by GW Pharmaceuticals Plc, H1 2016

Peripheral Neuropathic Pain - Pipeline by Nektar Therapeutics, H1 2016

Peripheral Neuropathic Pain - Pipeline by Phosphagenics Limited, H1 2016

Peripheral Neuropathic Pain - Pipeline by Spherium Biomed S.L., H1 2016

Peripheral Neuropathic Pain - Pipeline by Sunovion Pharmaceuticals Inc., H1 2016

Peripheral Neuropathic Pain - Pipeline by Zynerba Pharmaceuticals, Inc., H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Peripheral Neuropathic Pain Therapeutics - Recent Pipeline Updates, H1 2016

Peripheral Neuropathic Pain - Dormant Projects, H1 2016

Peripheral Neuropathic Pain - Discontinued Products, H1 2016

List of Figures

Number of Products under Development for Peripheral Neuropathic Pain, H1 2016

Number of Products under Development for Peripheral Neuropathic Pain - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Top 10 Targets, H1 2016

Number of Products by Stage and Top 10 Targets, H1 2016

Number of Products by Top 10 Mechanism of Actions, H1 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Achelios Therapeutics, Inc.
AnaBios Corporation
Chromocell Corporation
Eli Lilly and Company
GW Pharmaceuticals Plc
Nektar Therapeutics
Phosphagenics Limited
Spherium Biomed S.L.
Sunovion Pharmaceuticals Inc.
Zynerba Pharmaceuticals, Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll